We are live on
!
Find out more
ABG
Ally Bridge Group Portfolio holdings
AUM
$124M
1-Year Est. Return
249.88%
This Fund
S&P 500
This Quarter
Est. Return
-6.59%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$151M
AUM Growth
+$41.7M
(+38%)
Cap. Flow
+$58.7M
Cap. Flow
% of AUM
38.72%
Top 10 Holdings %
Top 10 Hldgs %
53.82%
Holding
52
New
30
Increased
1
Reduced
6
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$15.1M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
+$11.2M |
| 3 |
Sanofi
SNY
|
+$10.2M |
| 4 |
GSK
GSK
|
+$9.66M |
| 5 |
AMRN
Amarin Corp
AMRN
|
+$8.53M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$10.1M |
| 2 |
Cogent Biosciences
COGT
|
+$8.96M |
| 3 |
Lantheus
LNTH
|
+$7.59M |
| 4 |
Guardant Health
GH
|
+$6.45M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$6.25M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
| $12.7M | 8.36% |
+92,506
| New | +$15.1M |
|
|
2
Ultragenyx Pharmaceutical
RARE
$2.88B
| $8.99M | 5.93% |
+217,075
| New | +$11.2M |
|
|
3
Sanofi
SNY
$107B
| $8.74M | 5.77% |
+230,000
| New | +$10.2M |
|
4
Karyopharm Therapeutics
KPTI
$216M
| $8.35M | 5.51% |
+101,905
| New | +$7.61M |
|
5
Ironwood Pharmaceuticals
IRWD
$635M
| $7.69M | 5.08% |
+742,570
| New | +$8.42M |
|
6
Rocket Pharmaceuticals
RCKT
$376M
| $7.65M | 5.05% |
+479,506
| New | +$7.48M |
|
|
7
GSK
GSK
$104B
| $7.5M | 4.95% |
+255,000
| New | +$9.66M |
|
|
AMRN
8
Amarin Corp
AMRN
$292M
| $6.93M | 4.58% |
+317,914
| New | +$8.53M |
|
9
Alkermes
ALKS
$8.79B
| $6.7M | 4.42% |
+300,000
| New | +$7.8M |
|
|
MRSN
10
DELISTED
Mersana Therapeutics
MRSN
| $6.3M | 4.16% |
+37,262
| New | +$6.06M |
|
|
SYRS
11
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $5.59M | 3.69% |
868,403
+531,913
| +158% | +$4.32M |
|
|
HZNP
12
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $4.6M | 3.03% |
+74,262
| New | +$5.19M |
|
|
MDVL
13
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
| $4.57M | 3.02% |
117,898
| – | – |
|
14
Gossamer Bio
GOSS
$83.2M
| $4.52M | 2.98% |
377,000
-323,000
| -46% | -$4.01M |
|
15
Sana Biotechnology
SANA
$877M
| $4.41M | 2.91% |
+735,250
| New | +$5.31M |
|
|
16
argenx
ARGX
$53.8B
| $4.32M | 2.85% |
12,240
-27,130
| -69% | -$10.1M |
|
|
SAGE
17
DELISTED
Sage Therapeutics
SAGE
| $4.32M | 2.85% |
+110,222
| New | +$4.26M |
|
|
ALLK
18
DELISTED
Allakos
ALLK
| $3.66M | 2.42% |
+598,172
| New | +$2.51M |
|
19
Adicet Bio
ACET
$75.9M
| $3.48M | 2.29% |
+15,275
| New | +$3.88M |
|
|
LKFT
20
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
| $3.26M | 2.15% |
+76,489
| New | +$3.92M |
|
21
Repligen
RGEN
$8.31B
| $3.13M | 2.07% |
+16,724
| New | +$3.53M |
|
|
22
Cogent Biosciences
COGT
$6.68B
| $3.04M | 2.01% |
204,014
-653,338
| -76% | -$8.96M |
|
|
ISO
23
DELISTED
IsoPlexis Corporation Common Stock
ISO
| $2.62M | 1.73% |
1,522,364
-127,754
| -8% | -$315K |
|
24
Rapid Micro Biosystems
RPID
$103M
| $2.26M | 1.49% |
699,664
| – | – |
|
25
Atea Pharmaceuticals
AVIR
$390M
| $2.05M | 1.35% |
+360,000
| New | +$2.76M |
|
Similar funds
MP
EWP
WFA
VWM
EI
TC
IFO
CRW
Ally Bridge Group's Q3 2022 Portfolio in Review
As of Q3 2022, Ally Bridge Group held 52 positions worth $151M, up 38% from $110M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Ally Bridge Group deployed $58.7M of net new capital in Q3 2022, opening 30 new positions and adding to 1 existing holding. Its largest new stake was Seagen Inc. Common Stock: 92,506 shares worth $12.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was argenx, an estimated $10.1M trimmed.
- Ally Bridge Group's largest Q3 2022 buy was Seagen Inc. Common Stock: 92,506 shares worth $12.7M.
- Ally Bridge Group added most to Syros Pharmaceuticals, Inc. Common Stock in Q3 2022, an estimated $4.32M increase.
- Ally Bridge Group's biggest Q3 2022 reduction was argenx, cutting an estimated $10.1M.
- Ally Bridge Group fully exited Lantheus in Q3 2022, selling an estimated $7.59M.
- Ally Bridge Group's ten largest holdings make up 54% of its $151M portfolio in Q3 2022.
- Ally Bridge Group opened 30 new positions and closed 13 in Q3 2022.
- Ally Bridge Group's portfolio value rose 38% quarter-over-quarter to $151M.
Based on Ally Bridge Group's 13F filing for Q3 2022, filed 14 Nov 2022.